Clinical Trials Logo

Clinical Trial Summary

Transgender women (TGW) are at high risk for HIV infection, and are an important, under-researched population in sub-Saharan Africa. Globally, HIV acquisition risk among TGW is 13 times higher than other adults aged 15-49 years. In Uganda, HIV prevalence among TGW is 22% compared to 5.9% in the general population. Encouraging use of self-controlled HIV prevention tools - specifically, HIV self-testing (HIVST), STI self-sampling (STISS) and antiretroviral pre-exposure prophylaxis (PrEP) - to those testing HIV negative could decrease HIV incidence among African TGW. This R34 application proposes formative research and a pilot trial to develop an HIV prevention intervention for African transgender women (TGW). The investigators will evaluate whether peer-delivered combination HIV prevention increases testing uptake and empowers effective prevention decision making in TGW. Peer-led interventions are effective in increasing HIV and STI testing among other hard-to-reach vulnerable populations with high HIV prevalence but low testing coverage and are recommended by the World Health Organization. Exploring peer-delivery approaches to increase coverage of combination HIV prevention interventions is key to addressing research gaps in HIV epidemic control. However, little is known about the effectiveness of peer-delivered combination HIV prevention (HIVST, STISS and PrEP) for African TGW, or the best way to deliver care to this population. Key knowledge gaps include: 1) whether peer delivery increases testing rates and status knowledge, 2) the role of peers in creating demand for repeat testing and PrEP, and 3) how to optimize peer delivery of combination HIV prevention (HIVST, STISS and PrEP). To address these questions, this proposal seeks to conduct formative research to inform implementation of peer-delivered combination HIV prevention for African TGW (Aim 1), implement a pilot cluster randomized trial to evaluate the feasibility, acceptability and preliminary effectiveness of peer delivered combination HIV prevention (Aim 2), and conduct in-depth interviews to explore how peer-delivery of HIVST, STISS and PrEP influences prevention choices among TGW and sexual partners (Aim 3). This will be the first clinical trial, to our knowledge, to evaluate HIV self-testing and STI self-sampling in HIV-uninfected TGW. Pilot data from TGW and their partners will provide unique perspectives to inform HIV prevention delivery. The proposed proof-of-concept evaluation is uniquely positioned to improve prevention uptake for African TGW - a high-risk, marginalized, and underserved population. Rigorous application of mixed methodologies will generate actionable data for policy and programs, and provide a strong foundation for scalable implementation of cutting edge combination HIV prevention interventions for African TGW. The local transgender community is involved in study design, planning and implementation. This project is supported by the Ugandan Ministry of Health.


Clinical Trial Description

Transgender women (TGW) are at high risk for HIV infection, and are an important, under-researched population in sub-Saharan Africa. Globally, HIV acquisition risk among TGW is 13 times higher than other adults aged 15-49 years. In Uganda, HIV prevalence among TGW is 22% compared to 5.9% in the general population. Encouraging use of self-controlled HIV prevention tools - specifically, HIV self-testing (HIVST), STI self-sampling (STISS) and antiretroviral pre-exposure prophylaxis (PrEP) - among those testing HIV negative could decrease HIV incidence among African TGW and secondary transmission to their sexual partners. This study comprises formative research and a pilot trial to develop an HIV prevention intervention for African TGW. The investigators will evaluate whether peer-delivered combination HIV prevention increases testing uptake and empowers effective prevention decision making in TGW. Peer-led interventions are effective in increasing HIV and STI testing among other hard-to-reach vulnerable populations with high HIV prevalence but low testing coverage and are recommended by the World Health Organization (WHO). Exploring peer-delivery approaches to increase coverage of combination HIV prevention interventions is key to addressing research gaps in HIV epidemic control. However, little is known about the effectiveness of peer-delivered combination HIV prevention (HIVST, STISS and PrEP) for African TGW, or the best way to deliver care to this population. Key knowledge gaps include: 1) whether peer delivery increases testing rates and status knowledge, 2) the role of peers in creating demand for repeat testing and PrEP, and 3) how to optimize peer delivery of combination HIV prevention (HIVST, STISS and PrEP). To address these questions, this protocol describes formative research to inform implementation of peer-delivered combination HIV prevention for African TGW, followed by implementation of a pilot cluster randomized trial to evaluate the feasibility, acceptability and preliminary effectiveness of peer delivered combination HIV prevention, and in-depth interviews to explore how peer-delivery of HIVST, STISS and PrEP influences prevention choices among TGW and sexual partners. This will be the first clinical trial, to our knowledge, to evaluate HIV self-testing and STI self-sampling in HIV-uninfected TGW. Aim 1: Conduct formative research to inform implementation of peer-delivered combination HIV prevention for African TGW. Approach: Using the Social Ecological framework, the investigators will conduct in-depth interviews with TG peers, healthcare providers, civil society members, and Ministry of Health officials to: a) explore barriers and likely facilitators of HIVST, STISS and PrEP; and b) assess feasibility of respondent-driven sampling (RDS), the recruitment strategy for Aim 2. Hypothesis: Respondents will provide insights into the feasibility and acceptability of peer-delivered HIVST, STISS and PrEP, and RDS recruitment. Aim 2: Evaluate the feasibility, acceptability and preliminary effectiveness of peer-delivered combination HIV prevention (HIVST, STISS and PrEP) for African TGW by implementing a pilot cluster randomized controlled trial. Approach: To pilot-test the effectiveness of this peer-delivered combination HIV prevention intervention, 10 TGW peer groups (1 peer and 8 participants) will be randomized in a 1:1 ratio to either monthly peer delivery of HIVST, STISS and PrEP (intervention arm) or quarterly in-clinic HIV testing and PrEP prescription (control arm). All will enroll at clinic and initiate PrEP. In between quarterly clinic visits, trained peers will: a) deliver additional HIVST kits and PrEP refills; b) distribute STI self-sampling kits to TGW for own use and with regular partners; and c) use smart phone instructional videos showing TGW how to self-collect pharyngeal, rectal & urine specimens. The investigators will provide: i) free testing and treatment of Neisseria gonorrhoeae and Chlamydia trachomatis; and ii) peer-assisted partner notification services. Primary outcomes are intervention feasibility, acceptability & PrEP adherence. Hypothesis: Peer delivery will be feasible and acceptable, with higher uptake of testing and PrEP compared with control arm. Aim 3: Explore how peer-delivery of HIVST, STISS and PrEP influences prevention choices among TGW and sexual partners. Approach: To clarify the process through which peer-delivery may influence prevention choices, the investigators will conduct in-depth interviews with participants and their partners to assess perceptions and experiences with peer-delivered HIV/STI services, status disclosure, partner notification, behavior change and PrEP use. Hypothesis: Peer-delivered combination HIV prevention will empower TGW to engage in prevention services, facilitate partner testing and efficiently identify persons with undiagnosed HIV and/or STIs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04328025
Study type Interventional
Source Makerere University
Contact
Status Active, not recruiting
Phase N/A
Start date October 26, 2020
Completion date June 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Adherence to Anti- Retroviral Therapy (ART) Among People Living With Human Immunodeficiency Virus (HIV) Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2